23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion

The Lethal Triad and Trauma-Induced Coagulopathy

Exsanguinating trauma remains a leading cause of preventable mortality in critical care medicine. When severe tissue injury combines with systemic hypoperfusion, patients rapidly enter a self-propagating downward spiral historically known as the lethal triad of trauma: hypothermia, acidosis, and coagulopathy. Uninterrupted, this triad culminates in physiological exhaustion and death.

1. Hypothermia

Hypothermia in trauma is defined as a core body temperature $< 35^\circ\text{C}$ ($< 95^\circ\text{F}$). It arises from environmental exposure, loss of thermoregulatory shivering due to shock or sedation, administration of cold intravenous crystalloids and uncrossed blood products, and impaired metabolic heat production from cellular hypoperfusion. Coagulation is an enzymatic cascade: for every $1^\circ\text{C}$ reduction in core body temperature, the activity of clotting factor complexes declines by approximately 10%. Below $33^\circ\text{C}$, platelet adhesion and aggregation are severely blunted due to decreased glycoprotein Ib-IX-V complex binding to von Willebrand factor, even though standard laboratory coagulation tests (PT, aPTT, INR) performed in central laboratories at a standardized $37^\circ\text{C}$ will mask this in vivo enzymatic paralysis.

2. Metabolic Acidosis

Systemic tissue hypoperfusion forces cellular metabolism into anaerobic glycolysis, generating profound lactic acidosis with an arterial $\text{pH} < 7.20$ and a base deficit $> 6\text{ mEq/L}$. Hydrogen ions directly inhibit the enzymatic activity of the tenase (Factor VIIIa/IXa) and prothrombinase (Factor Va/Xa) complexes on the activated platelet phospholipid surface. At a pH of 7.0, thrombin generation falls by more than 50%, and when combined with hypothermia ($< 33^\circ\text{C}$), thrombin generation kinetics are suppressed by up to 80%. Acidosis also accelerates the degradation of fibrinogen and destabilizes established clot architecture.

3. Trauma-Induced Coagulopathy (TIC)

Modern understanding recognizes that trauma coagulopathy is not simply a late consequence of dilution and factor consumption, but an early, primary endogenous phenomenon termed Trauma-Induced Coagulopathy (TIC). Driven by extensive tissue injury and cellular shock, TIC involves:

• Endothelial Glycocalyx Degradation: Massive sympathoadrenal activation and shear stress shed syndecan-1 and heparin sulfate proteoglycans into the circulation, causing endogenous auto-heparinization.
• Protein C Activation: Thrombomodulin upregulation by hypoxic endothelium binds thrombin to activate Protein C, which irreversibly inactivates Factors Va and VIIIa.
• Hyperfibrinolysis: Ischemic tissues release excessive tissue-type plasminogen activator (tPA) while consuming plasminogen activator inhibitor-1 (PAI-1), triggering premature clot dissolution.
• Platelet Dysfunction: Circulating platelets exhibit marked receptor exhaustion and unresponsiveness to thrombin and ADP stimulation despite adequate numerical counts.

---

Damage Control Philosophy: Surgery vs. Resuscitation

Traditional trauma management emphasized early, exhaustive anatomical reconstruction during the index operative encounter. However, prolonged surgeries in the setting of severe hypothermia, acidosis, and coagulopathy invariably caused intraoperative death. This led to the modern paradigm of Damage Control Surgery (DCS) and its medical counterpart, Damage Control Resuscitation (DCR).

Damage Control Surgery (DCS)

Damage control surgery prioritizes physiological survival over anatomical completeness. It progresses through three distinct, coordinated stages:

1. Stage I (Abbreviated Surgery): Rapid laparotomy or thoracotomy focused solely on controlling surgical hemorrhage (ligation, vascular shunts, balloon tamponade, perihepatic packing) and gross enteral contamination (stapling off bowel perforations without anastomosis). The fascia is left open, and temporary abdominal closure (such as negative pressure wound therapy or a Bogota bag) is placed.
2. Stage II (ICU Resuscitation): The patient is transported directly to the intensive care unit for aggressive core rewarming, correction of coagulopathy, reversal of acidosis, and restoration of physiological reserve.
3. Stage III (Definitive Reconstruction): Once the lethal triad is fully resolved (typically 24 to 48 hours later), the patient returns to the operating room for pack removal, formal vascular reconstruction, gastrointestinal continuity restoration, and abdominal wall closure.

Damage Control Resuscitation (DCR)

Damage control resuscitation begins in the prehospital or trauma bay setting and continues in the ICU. Its three core tenets are:

1. Permissive Hypotension: Restricting fluid administration until active surgical or endovascular bleeding is controlled.
2. Hemostatic Resuscitation: Prioritizing balanced, uncrossed blood products (plasma, platelets, RBCs) over large-volume crystalloids.
3. Early Damage Control Adjuncts: Rapid administration of tranexamic acid, empirical calcium replacement, and aggressive active core rewarming.

---

Permissive Hypotension: Principles and Absolute Contraindications

Permissive hypotension (also termed hypotensive resuscitation or balanced hypovolemia) deliberately targets a lower-than-normal blood pressure during active non-compressible torso hemorrhage. The physiological targets are:

• Systolic Blood Pressure (SBP): $80\text{ to }90\text{ mmHg}$
• Mean Arterial Pressure (MAP): $50\text{ to }60\text{ mmHg}$

Physiological Rationale

Aggressive infusion of intravenous crystalloids or excessive blood products to reach "normal" blood pressures ($> 120\text{ mmHg}$) increases mechanical hydrostatic pressure across newly formed, friable vascular clots, dislodging them—a lethal clinical pitfall colloquially known as "popping the clot". Furthermore, large-volume crystalloids (0.9% normal saline or Lactated Ringer's) dilute circulating clotting factors, cool the patient, induce hyperchloremic metabolic acidosis, and accelerate endothelial glycocalyx shedding.

---

Massive Transfusion Protocols and the Balanced 1:1:1 Strategy

A Massive Transfusion Protocol (MTP) is an emergency institutional delivery mechanism designed to release pre-thawed plasma, platelets, and packed red blood cells in fixed, physiological ratios to combat trauma-induced coagulopathy and hemorrhagic shock.

Definitions of Massive Transfusion

• Historical: Transfusion of $\ge 10$ units of Packed Red Blood Cells (PRBCs) within a 24-hour period.
• Contemporary (Dynamic): Transfusion of $> 4$ units of PRBCs within 1 hour with anticipated ongoing bleeding, or replacement of $> 50\%$ of total circulating blood volume within 3 hours.

MTP Activation Triggers and Scoring Systems

Early activation before laboratory results return is critical. Validated clinical scoring tools include:

• Assessment of Blood Consumption (ABC) Score: Evaluates 4 bedside parameters (1 point each):
  1. Penetrating trauma mechanism
  2. Arrival SBP $\le 90\text{ mmHg}$
  3. Arrival Heart Rate $\ge 120\text{ bpm}$
  4. Positive Focused Assessment with Sonography for Trauma (FAST) An ABC score $\ge 2$ triggers immediate MTP activation with a sensitivity of ~75% and specificity of ~85%.
• Shock Index (SI): Heart Rate divided by SBP. A $\text{Shock Index} > 1.0$ (normal $0.5\text{ to }0.7$) indicates severe occult hypovolemia and independently predicts massive transfusion need.

The Balanced 1:1:1 Resuscitation Paradigm (The PROPPR Trial)

Historically, trauma patients received large volumes of crystalloid followed by PRBCs, with plasma and platelets added only after laboratory coagulopathy emerged. This approach led to severe dilutional coagulopathy.

The landmark PROPPR Trial (Pragmatic, Randomized Optimal Platelet and Plasma Ratios; JAMA 2015) randomized 680 severely bleeding trauma patients to a balanced 1:1:1 ratio (1 unit of platelets : 1 unit of FFP : 1 unit of PRBCs) versus a 1:1:2 ratio (1 unit of platelets : 1 unit of FFP : 2 units of PRBCs). While overall 24-hour and 30-day all-cause mortality did not differ significantly as the primary endpoint, the 1:1:1 group achieved significantly faster anatomical hemostasis (86% vs. 78%, $p=0.006$) and demonstrated a significant reduction in mortality from exsanguination within the first 24 hours (9.2% vs. 14.6%, $p=0.03$). Consequently, modern guidelines endorse a balanced 1:1:1 ratio as standard practice.

---

Viscoelastic Hemostatic Assays: TEG and ROTEM

Standard laboratory tests (PT/INR, aPTT, fibrinogen) are performed on platelet-poor plasma, take 45–60 minutes to process, and fail to assess platelet-fibrin interactions or hyperfibrinolysis. Viscoelastic Hemostatic Assays (VHAs)—predominantly Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM)—provide real-time, whole-blood dynamic evaluations of clot initiation, propagation, tensile strength, and dissolution within 10 to 20 minutes, enabling targeted, goal-directed factor replacement.

Viscoelastic Parameters and Product Matching

---

Tranexamic Acid: Evidence, Dosing, and the Critical 3-Hour Window

Tranexamic Acid (TXA) is a synthetic lysine analogue that competitively binds to lysine-binding sites on plasminogen molecules, blocking plasminogen from interacting with fibrin and preventing conversion to active plasmin, thereby suppressing fibrinolysis.

Clinical Evidence: CRASH-2 and CRASH-3

• CRASH-2 Trial (Lancet 2010): Enrolled 20,211 adult trauma patients with significant hemorrhage (SBP $< 90\text{ mmHg}$ or HR $> 110\text{ bpm}$) within 8 hours of injury. Early TXA administration significantly reduced all-cause mortality (14.5% vs. 16.0%, $p=0.0035$) and bleeding mortality (4.9% vs. 5.7%, $p=0.0077$) without increasing vascular occlusive events (DVT/PE, stroke, MI).
• CRASH-3 Trial (Lancet 2019): Evaluated TXA in isolated traumatic brain injury within 3 hours. TXA significantly reduced head-injury-related death in mild-to-moderate TBI (GCS 9–15), though patients with severe TBI (GCS 3–8) or bilaterally unreactive pupils derived no clear survival benefit.

The 3-Hour Time Window

Subgroup analysis from CRASH-2 revealed that the timing of TXA administration is paramount:

• TXA administered within $< 1\text{ hour}$ of injury reduced bleeding death risk by ~32% ($p<0.001$).
• TXA administered within 1 to 3 hours reduced bleeding death risk by ~21% ($p=0.03$).
• TXA administered AFTER 3 hours increased the risk of death due to bleeding (RR 1.44, 95% CI 1.12–1.84, $p=0.004$) and carries an elevated risk of microvascular thrombosis.

---

Transfusion Complications: Citrate Toxicity and Ionized Hypocalcemia

Massive transfusion introduces significant metabolic and physiological derangements that must be managed concurrently:

Citrate Toxicity and Hypocalcemia

All commercial blood products are anticoagulated with citrate (sodium citrate and citric acid), which prevents clotting by chelating free ionized calcium ($\text{Ca}^{2+}$). A healthy liver rapidly metabolizes citrate to bicarbonate. However, in trauma patients suffering from hypothermia, hepatic hypoperfusion, and shock, citrate clearance drops precipitously, resulting in severe ionized hypocalcemia ($\text{iCa}^{2+} < 0.9\text{ mmol/L}$).

• Clinical Consequences: Ionized calcium is Factor IV in the coagulation cascade; without adequate $\text{iCa}^{2+}$, assembly of the tenase and prothrombinase complexes fails, rendering coagulation non-functional regardless of administered factor volumes. Hypocalcemia also blunts cardiac myocyte contractility, induces peripheral vasodilation, causes refractory hypotension, and prolongs the QTc interval, predisposing to polymorphic ventricular arrhythmias.
• Management Target: Ionized calcium must be checked every 30 to 60 minutes during active MTP resuscitation. Clinicians should empirically administer $1\text{ to }2\text{ g}$ of intravenous calcium chloride (or $3\text{ g}$ calcium gluconate) for every 4 units of citrated blood components transfused, titrating to maintain $\text{iCa}^{2+} \ge 1.1\text{ to }1.3\text{ mmol/L}$. Calcium chloride contains three times more elemental calcium per gram than calcium gluconate and does not require hepatic metabolism, making it the preferred formulation in central venous access.

Other MTP Complications

• Hyperkalemia: Red blood cells leak intracellular potassium during refrigerated storage. Rapid transfusion of multiple units can trigger life-threatening hyperkalemia ($> 6.5\text{ mEq/L}$), especially with concurrent renal hypoperfusion and acidosis.
• Hypothermia: Blood products are stored at $1^\circ\text{C}$ to $6^\circ\text{C}$. Rapid blood warmers (e.g., Belmont, Level 1) capable of delivering $40^\circ\text{C}$ to $42^\circ\text{C}$ fluids at high flow rates ($> 500\text{ mL/min}$) are mandatory to prevent worsening core hypothermia.

Massive Transfusion Protocol Targets